ENHA News & Events

Enhanced announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. Co-Created with Hafthor "Thor" Bjornsson, World's Strongest Man Champion and the most decorated strength athlete in the history of the sport, The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The company said, "Thor's Protocol includes three clinician-prescribed products, each personalized to the individual's lab results and health profile. Testosterone Injections: Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor's protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+: NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+'s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Low-Dose Tadalafil: Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual."

Enhanced Group announced the closing of the initial tranche of its previously disclosed $50M private investment in public equity financing. The remaining tranches are expected to close following customary regulatory and stock exchange approvals. The financing is led by Apeiron Investment Group, the family office of Enhanced Co-Founder and Chairman Christian Angermayer, with participation from Co-Founder and CEO Maximilian Martin, with ticket sizes of $20M and $5M respectively, as well as leading global institutional investors. Following the inaugural Games, existing sponsors have expressed interest in renewing for 2027, while inbound demand from prospective sponsors continues to accelerate. The Company currently expects the sports business to achieve profitability in 2027.